7/27/2018 | CV | Market Commentary: Twitter sees buyers on downturn; newer Twitter Cs flat to 0.25 point better on hedge
|
7/27/2018 | CV | Market Commentary: Morning Commentary: Twitter moving lower as shares drop; Pacira quiet after expanding
|
4/12/2018 | CV | Market Commentary: Transocean convertibles in focus; primary quiet; biotech sector firm; Caesars active
|
4/9/2018 | CV | Market Commentary: Convertibles off to a ‘Monday’ opening; Pure Storage, Zendesk below par; Tesla active
|
4/9/2018 | CV | Market Commentary: Morning Commentary: Convertibles space off to a ‘Monday’ opening; Pure Storage below par
|
7/25/2017 | CV | Market Commentary: Novavax loses ground; Pacira trial results disappoint; Medicines’ data positive, bonds flat
|
3/13/2017 | CV | Pacira greenshoe exercised, lifts 2.375% convertibles to $345 million
|
3/9/2017 | CV | Market Commentary: Pacira retreats from post-pricing highs; Nabors trends lower; oil names remain under pressure
|
3/9/2017 | CV | Market Commentary: Morning Commentary: Pacira comes off highs; Nabors trends lower, in line with broader market
|
3/8/2017 | CV | Market Commentary: Pacira deal prices rich, pops above par; Impax improves on strategic review; Chesapeake drops
|
3/8/2017 | CV | Market Commentary: Morning Commentary: Pacira deal prices rich, pops above par; Impax rises on strategic review news
|
3/8/2017 | CV | New Issue: Pacira Pharmaceuticals sells $300 million convertibles due 2022 at 2.375%, up 37.5%
|
3/7/2017 | CV | Market Commentary: Weatherford rises as new CEO tapped; DISH pops on S&P 500 add; Square comes in; Pacira on tap
|
3/7/2017 | CV | Market Commentary: Morning Commentary: Weatherford rises as new CEO tapped; DISH pops on S&P 500 add; Pacira on deck
|
3/6/2017 | CV | Market Commentary: Convertibles flat to lower as broader markets sink; Lumentum slips; Pacira launches deal
|
3/6/2017 | CV | Pacira Pharmaceuticals to sell $300 million five-year convertibles at 2.75%-2.875%, up 27.5%-32.5%
|
8/30/2016 | CV | Market Commentary: Convertibles flat as equities tick lower; Pacira, Cypress shares up; TCP Capital to price
|
5/2/2016 | CV | Market Commentary: GNC trades up on possible sale; Whiting mostly quiet after earnings disappoint; Cobalt up
|
1/22/2016 | CV | Market Commentary: Chesapeake Energy preferreds, bonds mixed after dividend suspended to buy back debt
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
9/25/2015 | CV | Market Commentary: Biotechnology names lower outright; AMAG Pharmaceuticals moves in line in active trade
|
4/16/2015 | CV | Market Commentary: SanDisk lower outright, edges up on swap; Teva below parity; planned Pernix looks cheap
|
9/25/2014 | CV | Market Commentary: Convertibles hit as high-yield, equities sell off; new SolarCity drops out of the gate
|
1/24/2013 | CV | Market Commentary: New KB Home trades flat on hedge on debut; Auxilium offering upsized, talked terms revised
|
1/23/2013 | CV | Pacira greenshoe exercised, lifting 3.25% convertibles to $120 million
|
1/17/2013 | CV | New Issue: Pacira prices upsized $110 million six-year convertibles to yield 3.25%, up 32.5%
|
1/17/2013 | CV | Market Commentary: New Pacira surges on debut; planned Theravance seen cheap; planned Solazyme lacks borrow
|
1/16/2013 | CV | Market Commentary: InterMune notches stellar debut; Pacira sees revised terms; Cobalt steady dollar neutral
|
1/16/2013 | CV | Talk on Pacira's planned $100 million six-year convertibles revised to 3.25% yield, up 32%
|
1/15/2013 | CV | Pacira Pharmaceuticals to price $100 million six-year convertibles at 3.5%-4%, up 27.5%-32.5%
|
1/15/2013 | CV | Market Commentary: Amgen sees sellers ahead of maturity; Gilead Ds better; Lennar slips; Pacira to price
|
3/27/2012 | CVHYPF | Pacira files $150 million shelf covering stock, preferreds and debt
|